Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
Kyorin Chemical Laboratory was established.
The company was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
The Okaya Plant was started
The medical journal bulletin “Doctor Salon” was started.
Behyd, a diuretic and antihypertensive agent, was launched.
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
The Head Office was completed in Kanda Surugadai.
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
The nogi Plant was started.
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.
Hydroxyethylstarch (HES) was licensed to Pfrimmer (Germany, present Baxter Deutschland).
Central Research Laboratories were established.
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).
Mucodyne, a mucoregulant, was launched.
Norfloxacin (NFLX) was licensed to Astra (Sweden, present AstraZeneca) and Boots (U.K., present Abbvie).
Norfloxacin (NFLX) was licensed to American Home Products (U.S.A., present Pfizer).
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
Fleroxacin (FLRX), an antibacterial agent, was licensed to F. Hoffmann-La Roche (Switzerland).
APLACE, an agent for gastritis & gastric ulcer, was launched.
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
BACCIDAL Tablet for Children was launched.
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.
Megalocin (FLRX), a long-acting new quinolone agent, was launched.
Research Center (now Development Research Laboratories) was founded by integrating Research Center of Organic Syntheses,
Technical Center of Development, Technical Center of Product Formulation and Technical Center of Safety Assessment.
The Noshiro Plant was started.
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
Pentasa Tablet, a treatment for ulcerative colitis and Crohn’s disease, was launched.
Milton, an effervescent disinfectant business, was acquired from P&G.
Listed on the Tokyo Stock Exchange, Second Section.
Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin-eyedrops was licensed to Allergan (U.S.A.).
A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.
Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
A subsidiary company, Kyorin Europe GmbH (Germany), was established.
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
The new Noshiro Plant began operating.
A business transfer agreement was made with the Fresenius Kabi AG Group in Germany concerning Hespander and Salinhes, plasma substitutes and hemodilution agents.
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
Kipres Fine Granules 4mg, a bronchial asthma treatment drug, was launched.
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
Pentasa Tablet 500, a treatment for ulcerative colitis and Crohn’s disease, was launched.
Marketing rights in China were granted to Senju Pharmaceutical for Gatifloxacin Ophthalmic Solution.
A license agreement for Neramexane, a tinnitus drug, was made with Merz Pharmaceuticals (Germany) for the Japan region.
Mucodyne DS 50%, a mucoregulant, was launched.
Uritos Orally Disintegrating (OD) Tablets 0.1mg, an overactive bladder drug, was launched
Transfer of business related to a topical antifungal prescription drug Pekiron cream 0.5% to Galderma S.A. (Switzerland)
RUBYSTA, a multi-purpose disinfectant cleaner, was launched.
Head office moved to Ochanomizu sola city in Kanda Surugadai.
Pentasa Suppositories 1g, a treatment for ulcerative colitis, was launched.
Flutiform, a combination drug for asthma treatment, was launched.
Signed a license agreement concerning Vibegron, a therapeutic agent for overactive bladder, with Merck & Co. (U.S.A.).
Established the WATARASE Research Center.
FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)
Eklira Genuair, a treatment for COPD, was launched.
Pentasa Granules 94%, a treatment for ulcerative colitis and Crohn’s disease, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched
Beova Tablets 50mg a treatment of OAB drug was launched
GeneSoC®, a microchannel-based genetic measurement device, was launched.
Lasvic Tablets 75mg an oral quinolone antibacterial agent was launched
Lasvic Intravenous Drip Infusion Kit 150mg, an injectable new quinolone antibacterial agent was launched